Medpace Holdings (MEDP) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Medpace Holdings

NasdaqGS•Healthcare•Diagnostics & Research

$677.40+0.63(<0.01%)Market open

Market Cap

$18.11B

P/E

35.0x

P/S

6.4x

P/B

31.0x

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

How this company scores

ExcellentMetricSide Score: 83/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability25/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality18/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 35.0x5y range 21.5x – 62.9x

Currently near its 20-quarter median.

P/S · 6.4x5y range 4.0x – 10.0x

Currently near its 20-quarter median.

P/B · 31.0x5y range 11.2x – 52.1x

Price & Volume

Market Cap $18.11B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.84B
Q. Revenue: $716.00M
TTM EBITDA: $634.46M
TTM Op. Income: $607.14M
Q. Op. Income: $165.54M
TTM Net Income: $517.83M
Q. Net Income: $137.46M
EPS: $4.92
Shares Out.: $27.94M

$2.84B in TTM revenue grew 20.4% YoY, reaching $716.00M last quarter. TTM EBITDA of $634.46M and TTM operating income of $607.14M show growth is flowing through to the bottom line. TTM net income of $517.83M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 24.0%
Op. Margin: 23.1%
Net Margin: 19.2%

Op. margin of 23.1% is up 1.6% YoY — cost efficiency is improving. Net margin at 19.2% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 35.0x
P/S Ratio: 6.4x
P/B Ratio: 31.0x

At 35.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.4x and P/B of 31.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $2.30B
Cash: $705.32M
Long-Term Debt: N/A
Book Value: $584.94M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $216.60M
TTM Free Cash Flow: $667.63M
FCF Margin: 23.5%
FCF / Net Income: 1.3

TTM FCF of $667.63M on $216.60M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.